Search
Close this search box.
Trending now:  
Improved Clinical Outcomes with Intravascular Imaging-Guided PCI: Impact of Standardized Optimization Protocols
Influence of Chest Compression Duration on Pediatric In-Hospital Cardiac Arrest Survival
Gender Disparities in Outcomes of Invasive versus Conservative Strategies for Coronary Artery Disease: Insights from the ISCHEMIA Trial
RELIEVE-HF: Interatrial shunt in patients with heart failure
Expedited transfer to cardiac arrest center vs standard care for non-ST elevation out-of-hospital cardiac arrest

Content for healthcare professionals only

News |

AHA 2023 Highlights

15 Nov 2023
AHA 2023 Highlights

The American Heart Association (AHA) Scientific Sessions 2023 were held in Philadelphia, Pennsylvania (PA), on November 11-13, 2023. Below are summary highlights curated from key clinical trial presentations and publications stemming from the AHA Scientific Sessions 2023.

DAPA-MI Trial1,2: (NCT04564742) The DAPA-MI trial, a registry-based randomized study involving 4017 non-type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF)-free patients with recent myocardial infarction (MI) and impaired left ventricular (LV) function, compared the effects of 10 mg dapagliflozin (n=2019) to placebo (n=1998) taken once daily (OD). The primary endpoint was a composite, in hierarchical order, of death, HF hospitalization, non-fatal MI, atrial fibrillation (AF)/flutter, T2DM onset, New York Heart Association Functional Classification (NYHA class), and ≥5% weight decrease (win-ratio analysis driven by the added cardiometabolic [CM] outcomes); the secondary endpoint excluded the weight criterion. Over the 12-month follow-up, the dapagliflozin group had more positive outcomes than placebo, 32.9% vs. 24.6% (win ratio 1.34; 95% confidence interval [CI], 1.20-1.50; p<0.001), with the benefit remaining even without considering weight loss. Therefore, while significant benefits were seen in improvements in CM outcomes, cardiovascular (CV) deaths and HF hospitalizations were nearly identical for dapagliflozin and placebo (2.5% vs 2.6%), with no other noteworthy differences in individual ‘hard’ endpoints.

ORBITA-23: (NCT03742050)The Percutaneous Coronary Intervention (PCI) for Stable Angina: A Randomised, Placebo-Controlled Trial comprised 301 patients with stable angina randomised to PCI (n=151) or to placebo (n=150), assessing the primary endpoint of angina symptom score (0-79 scale; higher score indicating worse outcomes) based on daily angina episodes, antianginal medication use, and clinical events, which included unblinding due to severe angina or acute coronary syndrome (ACS), or death. Results showed ischemia was present in one cardiac territory in 80% (242), two territories in 17% (52), and three territories in....

 

To read full highlights article please login or sign up as a member.

Share:

Related Topics

Related Articles